$ADXS Up to date company activities and other impo
Post# of 72711
$ADXS
DD Notes ~ http://www.ddnotesmaker.com/ADXS
##### recent news/filings ~ source: finance.yahoo.com
Thu, 24 Apr 2014 13:56:17 GMT ~ Advaxis to Present at 2014 American Society of Clinical Oncology Annual Meeting
- PRINCETON, N.J., April 24, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced that two abstracts related ...
read full: http://www.noodls.com/view/47BE6CD35A6847F506...E6CF75F173
*********************************************************
Thu, 24 Apr 2014 12:45:00 GMT ~ Advaxis to Present at 2014 American Society of Clinical Oncology Annual Meeting
- PRINCETON, N.J. -- Advaxis, Inc. , a biotechnology company developing the next generation of cancer immunotherapies, today announced that two abstracts related to ADXS-HPV (ADXS11-001), the Company's lead ...
read full: http://finance.yahoo.com/news/advaxis-present...00451.html
*********************************************************
Mon, 14 Apr 2014 11:30:00 GMT ~ Japan Patent Office Issues Advaxis a Notice of Allowance for Two Patent Applications Covering Its Cancer Immunotherapy Platform Technology
- PRINCETON, N.J. -- Advaxis, Inc. , a biotechnology company developing the next generation of cancer immunotherapies, announced that the Japan Patent Office issued to Advaxis two notices of allowance for ...
read full: http://finance.yahoo.com/news/japan-patent-of...00587.html
*********************************************************
Tue, 01 Apr 2014 21:00:35 GMT ~ ADVAXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and
read full: http://biz.yahoo.com/e/140401/adxs8-k.html
*********************************************************
Tue, 01 Apr 2014 11:30:00 GMT ~ Advaxis Receives Notice of Allowance From U.S. Patent and Trademark Office for Three Patent Applications With Multiple Claims Covering Its Cancer Immunotherapy Platform Technology
- PRINCETON, N.J. -- Advaxis, Inc. , a biotechnology company developing the next generation of cancer immunotherapies, announced that the United States Patent and Trademark Office (USPTO) has issued a notice ...
read full: http://finance.yahoo.com/news/advaxis-receive...00088.html
*********************************************************
##### chart ~ source: stockcharts.com
stockcharts.com/c-sc/sc?s=ADXS&p=D&b=5&g=0&id=p95448242713
##### chart ~ source: eoddata.com
http://chart.eoddata.com/?e=OTCBB&s=ADXS&...D&b=BB
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ADXS/company-info
Ticker: $ADXS
OTC Market Place: Not Available
CIK code: 0001100397
Company name: Advaxis, Inc.
Company website: http://www.advaxis.com
Incorporated In: DE, USA
##### extra dd links
Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?actio...p;count=40
Latest filings: http://www.otcmarkets.com/stock/ADXS/filings
Latest financials: http://www.otcmarkets.com/stock/ADXS/financials
Latest news: http://www.otcmarkets.com/stock/ADXS/news - http://finance.yahoo.com/q/h?s=ADXS+Headlines
Major holdings: http://data.cnbc.com/quotes/ADXS/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=ADXS+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/ADXS.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=ADXS
RegSho: http://www.regsho.com/tools/symbol_stats.php?...rch=search
DTCC: http://search2.dtcc.com/?q=Advaxis%2C+Inc.&am...ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&am...xis%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results...=0&y=0
WHOIS: http://whois.domaintools.com/http://www.advaxis.com
Alexa: http://www.alexa.com/siteinfo/http://www.advaxis.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.advaxis.com
Short Sales: http://www.otcmarkets.com/stock/ADXS/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/ADXS/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/ADXS/research
Historical Prices: http://finance.yahoo.com/q/hp?s=ADXS+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=ADXS+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=ADXS+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=ADXS+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=ADXS+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=ADXS+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=ADXS
Balance Sheet: http://finance.yahoo.com/q/bs?s=ADXS
Cash Flow: http://finance.yahoo.com/q/cf?s=ADXS+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/ADXS
Bloomberg: http://www.bloomberg.com/quote/ADXS:US
Morningstar: http://quotes.morningstar.com/stock/s?t=ADXS
Bussinessweek: http://investing.businessweek.com/research/st...icker=ADXS
Barchart: http://www.barchart.com/quotes/stocks/ADXS
OTC Short Report: http://otcshortreport.com/index.php?index=ADXS
Investopedia: http://www.investopedia.com/markets/stocks/ADXS/?wa=0
http://www.pennystocktweets.com/stocks/profile/ADXS
##### last known share structure ~ source: otcmarkets.com
Market Value: $51,439,982 a/o Apr 25, 2014
Shares Outstanding: 14,016,344 a/o Mar 13, 2014
Float: Not Available
Authorized Shares: 25,000,000 a/o Jul 15, 2013
Par Value: Not Available
##### business description ~ source: otcmarkets.com
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein(s) that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.ADXS-HPV is currently being evaluated in four clinical trials for human papillomavirus (HPV)-associated cancers: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI U.S. study, Clinical Trials.gov Identifier NCT01266460), head & neck cancer (CRUK study, Clinical Trials.gov Identifier NCT01598792), and anal cancer (BrUOG study, Clinical Trials.gov Identifier NCT01671488). Advaxis has over 15 distinct immunotherapies in various stages of development, developed directly by Advaxis and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research - UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.Less >>
DD Notes ~ http://www.ddnotesmaker.com/ADXS